Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Zojer

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Memo|September 22, 2021
SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?Niklas Zojer
Nature Reviews. Clinical Oncology|March 31, 2010
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myelomaHeinz Ludwig, Niklas Zojer
Wiener Klinische Wochenschrift|June 30, 2007
[Anemias]Niklas Zojer, Heinz Ludwig
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 22, 2011
Supportive therapy in multiple myelomaHeinz Ludwig, Niklas Zojer
Hematology. American Society of Hematology. Education Program|December 10, 2017
Fixed duration vs continuous therapy in multiple myelomaHeinz Ludwig, Niklas Zojer
Best Practice & Research. Clinical Haematology|December 12, 2007
Supportive care in multiple myelomaHeinz Ludwig, Niklas Zojer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Correspondence re: T. Fehm et al., Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res., 8: 2073-2084, 2002Michael Fiegl, Brigitte Kircher, Niklas Zojer
Treatments in Endocrinology|June 22, 2005
Current management strategies for hypercalcemiaMartin Pecherstorfer, Karin Brenner, Niklas Zojer
Oncotargets and Therapy|July 10, 2010
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaMartina Lehnert, Heinz Ludwig, Niklas Zojer
European Journal of Haematology|July 12, 2008
Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetanNiklas Zojer, Siroos Mirzaei, Heinz Ludwig
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Memo|September 22, 2021
SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?Niklas Zojer
Nature Reviews. Clinical Oncology|March 31, 2010
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myelomaHeinz Ludwig, Niklas Zojer
Wiener Klinische Wochenschrift|June 30, 2007
[Anemias]Niklas Zojer, Heinz Ludwig
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 22, 2011
Supportive therapy in multiple myelomaHeinz Ludwig, Niklas Zojer
Hematology. American Society of Hematology. Education Program|December 10, 2017
Fixed duration vs continuous therapy in multiple myelomaHeinz Ludwig, Niklas Zojer
Best Practice & Research. Clinical Haematology|December 12, 2007
Supportive care in multiple myelomaHeinz Ludwig, Niklas Zojer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Correspondence re: T. Fehm et al., Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res., 8: 2073-2084, 2002Michael Fiegl, Brigitte Kircher, Niklas Zojer
Treatments in Endocrinology|June 22, 2005
Current management strategies for hypercalcemiaMartin Pecherstorfer, Karin Brenner, Niklas Zojer
Oncotargets and Therapy|July 10, 2010
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaMartina Lehnert, Heinz Ludwig, Niklas Zojer
European Journal of Haematology|July 12, 2008
Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetanNiklas Zojer, Siroos Mirzaei, Heinz Ludwig
Pageof 7